Literature DB >> 18294274

Production and characterization of highly tumor-specific rat monoclonal antibodies recognizing the extracellular domain of human L-type amino-acid transporter 1.

Yoshiya Ohno1, Kentaro Suda, Kazue Masuko, Hideki Yagi, Yoshiyuki Hashimoto, Takashi Masuko.   

Abstract

L-type large amino acid transporter (LAT) 1, the first light chain (lc) of cluster of differentiation 98 (CD98) to be identified, is associated with the heavy chain (hc) of CD98 and expressed on the surface of various tumor cells irrespective of their origin. Because LAT1 is a 12-pass membrane protein and its possible immunogenic extracellular region is very small, specific monoclonal antibodies (mAb) had not been developed. We report the successful preparation and characterization of mAb recognizing the extracellular domain of human LAT1 protein. Two mAb were selected from hybridoma clones established by fusing mouse myeloma cells and spleen cells from rats immunized against RH7777 rat hepatoma cells expressing recombinant green fluorescent protein fused to human LAT1 protein. Designated SOL22 and SOL69, these mAb specifically reacted with the extracellular domain of LAT1 on cells transfected with cDNA of LAT1, but not with cells transfected with cDNA of other CD98 lc, namely, LAT2, y(+)LAT1, y(+)LAT2, and xCT amino acid transporters. These mAb immunoprecipitated 35- and 90-kDa proteins under reducing conditions in extracts prepared from human HeLa tumor cells, indicating the existence of intermolecular disulfide bonds between cysteine residues in the 90-kDa hc and 35-kDa lc (LAT1). SOL22 and SOL69 mAb reacted with a wide variety of living unfixed human tumor cell lines, but were only weakly reactive with HEK293F human embryonic kidney cells and human peripheral blood cells. Comparative immunohistochemical analyses of normal human tissues with anti-CD98 hc and anti-LAT1 revealed LAT1 to be an excellent molecular target for antibody therapy, possibly even superior to CD98 hc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18294274     DOI: 10.1111/j.1349-7006.2008.00770.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  12 in total

Review 1.  Therapeutic antibodies directed at G protein-coupled receptors.

Authors:  Catherine J Hutchings; Markus Koglin; Fiona H Marshall
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

2.  A combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2 (CXCR2).

Authors:  Ronald S Boshuizen; Catherine Marsden; Johan Turkstra; Christine J Rossant; Jerry Slootstra; Clive Copley; Klaus Schwamborn
Journal:  MAbs       Date:  2014       Impact factor: 5.857

Review 3.  Nutrient transporters: the Achilles' heel of anabolism.

Authors:  Alison N McCracken; Aimee L Edinger
Journal:  Trends Endocrinol Metab       Date:  2013-02-08       Impact factor: 12.015

Review 4.  Heteromeric Solute Carriers: Function, Structure, Pathology and Pharmacology.

Authors:  Stephen J Fairweather; Nishank Shah; Stefan Brӧer
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Anti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cells.

Authors:  Kazue Masuko; Shogo Okazaki; Mayumi Satoh; Goh Tanaka; Tatsuya Ikeda; Ryota Torii; Eri Ueda; Takashi Nakano; Masaaki Danbayashi; Tomoyo Tsuruoka; Yoshiya Ohno; Hideki Yagi; Noritsugu Yabe; Hideaki Yoshida; Tomoyuki Tahara; Shiro Kataoka; Taichi Oshino; Takayuki Shindo; Shin-ichiro Niwa; Takatsugu Ishimoto; Hideo Baba; Yoshiyuki Hashimoto; Hideyuki Saya; Takashi Masuko
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

6.  Promotion of malignant phenotype after disruption of the three-dimensional structure of cultured spheroids from colorectal cancer.

Authors:  Jose M Piulats; Jumpei Kondo; Hiroko Endo; Hiromasa Ono; Takeshi Hagihara; Hiroaki Okuyama; Yasuko Nishizawa; Yasuhiko Tomita; Masayuki Ohue; Kouki Okita; Hidejiro Oyama; Hidemasa Bono; Takashi Masuko; Masahiro Inoue
Journal:  Oncotarget       Date:  2018-03-23

7.  Inhibition of tumor formation and metastasis by a monoclonal antibody against lymphatic vessel endothelial hyaluronan receptor 1.

Authors:  Yuta Hara; Ryota Torii; Shiho Ueda; Erina Kurimoto; Eri Ueda; Hiroshi Okura; Yutaka Tatano; Hideki Yagi; Yoshiya Ohno; Toshiyuki Tanaka; Kazue Masuko; Takashi Masuko
Journal:  Cancer Sci       Date:  2018-08-26       Impact factor: 6.716

8.  Production of antibodies against multipass membrane proteins expressed in human tumor cells using dendritic cell immunization.

Authors:  Takahiko Tamura; Joe Chiba
Journal:  J Biomed Biotechnol       Date:  2009-04-15

9.  Imaging the L-type amino acid transporter-1 (LAT1) with Zr-89 immunoPET.

Authors:  Oluwatayo F Ikotun; Bernadette V Marquez; Chaofeng Huang; Kazue Masuko; Miyamoto Daiji; Takashi Masuko; Jonathan McConathy; Suzanne E Lapi
Journal:  PLoS One       Date:  2013-10-15       Impact factor: 3.240

10.  Immuno-PET Imaging of HER3 in a Model in which HER3 Signaling Plays a Critical Role.

Authors:  Qinghua Yuan; Takako Furukawa; Takahiro Tashiro; Kouki Okita; Zhao-Hui Jin; Winn Aung; Aya Sugyo; Kotaro Nagatsu; Hiroko Endo; Atsushi B Tsuji; Ming-Rong Zhang; Takashi Masuko; Masahiro Inoue; Yasuhisa Fujibayashi; Tsuneo Saga
Journal:  PLoS One       Date:  2015-11-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.